Introduction
The goal of cancer gene therapy is to introduce new genetic material into target cells without toxicity to non-target tissues. The patient with recurrent or metastastic cancer is often considered incurable. A variety of chemotherapeutic agents has been used alone, and in combination, for the treatment of recurrent oral squamous cell carcinoma. However, chemotherapy is associated with well-known toxicities and has demonstrated no clear impact on survival in patients with recurrent oral cancer. Local and regional disease control is paramount, underscoring an urgent need for more effective therapies. Gene therapy has the potential to target cancer cells while sparing normal tissues. Such a strategy may be useful for recurrent disease as well as in the adjuvant setting (i.e., at the resected tumor margins).
Although gene therapy as a treatment for disease holds great promise, progress in developing effective clinical protocols has been slow. The problem lies in the development of safe and efficient gene-delivery systems.
This review will evaluate the problems and the potential solutions in this new field of medicine.
In order for target cells to manufacture the protein products of the introduced gene, the exogenous genetic material must be delivered to the cell's nucleus. This process of transfection exists in 2 classes of vectors: Viral and non-viral. The viral technique is associated with increased technical demands and an increased risk of virus-associated toxicity. However, viral vectors have been engineered for safety by making them replication incompetent. It is the viral ability to efficiently infect cells and in this process to transfer DNA to the host without invoking an immune response that makes viruses attractive as vectors. These altered viruses can be propagated in cell lines specialized to provide the necessary absent viral functions. [1, 2] Genetic material can be transferred via a vector that is defined as the vehicle that is used to deliver the gene of interest. The ideal vector would transfer a precise amount of genetic material into each target cell, thereby allowing for expression of the gene product without causing toxicity.
The structure of DNA was unraveled by Watson and Crick in 1953, and two decades later Arber, Nathans and Smith discovered DNA restriction enzymes, which led to the rapid growth in the field of recombinant DNA technology. From expressing cloned genes in bacteria to expressing foreign DNA in transgenic animals, DNA is now slated to be used as a therapeutic agent to replace defective genes in patients suffering from genetic disorders or to kill tumor cells in cancer patients. Gene therapy provides modern medicine with new perspectives that were unthinkable two decades ago. Progress in molecular biology and especially, molecular medicine is now changing the basics of clinical medicine. A variety of viral and non-viral possibilities are available for basic and clinical research. This review summarizes the delivery routes and methods for gene transfer used in gene therapy. achieve the level and duration of trans-genic expression sufficient to correct the defect and be non-immunogenic and safe. [1] [2] [3] Gene transfer via the viral vectors is called transduction while transfer via the non-viral vectors is called transfection. [4] Chemical transfection introduces DNA by calcium phosphate, lipid, or protein complexes. Calcium phosphate, DEAE-dextran, liposomes, and lipoplexes (for oral delivery of gene) surfactants and perfluro chemical liquids for aerosol delivery of gene. Physical transfection of genes can be accomplished by electroporation, microinjection, or use of ballistic particles. Parenteral injections, micro-injections, aerosol, electroporation (high voltage current is passed to the target cell to produce pores on the cell surface through which transgene enters the cell) and gene guns. [5, 6] Electroporation therapy with intralesional bleomycin has been reported to be a technically simple outpatient technique where high-voltage electric impulses can be delivered into a neoplasm by transiently increasing cell membrane permeability to large molecules, including cytotoxic agents, thus causing localized progressive necrosis. Electroporation can treat bulky tumors (>2 cm) with complete penetration. [5, 7] 
Viral Vectors
These are more promising system of gene delivery with various advantages over physical and chemical method:
1. Gene transferred is more efficient and specific than physical and chemical method 2. Multiple and repeated doses are required in case of physical and chemical method, whereas in case of viral vector even a single dose is sufficient. [7, 8] 
Transfer of the Genetic Material to the Cells
Although, systemic intravenous route can be applied to deliver the genetic material to the cells, local delivery methods are more commonly used such as surgical, percutaneous, US and computed tomography guided and by means of catheters.
The viral vectors can be divided into two types:
Integrating and non-integrating viral vectors. The former, such as, retroviral, lentiviral, and adeno-associated viral vectors, can integrate into the human genome; whereas the non-integrating vector (e.g., adenoviralvector) is maintained in the nucleus without integrating into the chromosomal DNA, so that the transgene is apt to lose during cell division and expression of the foreign gene is transient. In apackaging cell, the essential components for further propagating of viruses can be provided in trans, which enable the viral vectors to be packaged as the viral particles and to deliver genes to the targeted cells.
Certainly, this is a dead-end infection, because the vectors lack the essential components for viruses' propagation.
Recombinant viral vectors can lead to the generation of infectious parental viruses. This is a principle frequently used in viral vector design in gene therapy. [4] 
Retroviruses
Retroviruses are RNA viruses that carry a gene for a reverse transcriptase that transcribes the viral genetic material into a double stranded DNA intermediate. This
DNA intermediate is then incorporated into the host
DNA allowing the host cell machinery to produce all the necessary viral components. Additionally, because the viral genome is stably integrated into the host DNA, any modification that has been made will be passed to all daughter cells that are derived from the transfected cell currently; the most common retrovirus used is derived from the murine leukemia virus.
In general, retroviruses have been used for ex vivo gene therapy applications as they are unable to efficiently infect non-dividing cells. Using different viral envelope proteins that recognize different receptors can vary the range of cells that can be transduced, but still does not provide much specificity.
Limitations of Retroviral Vectors
The difficulty is that, because retroviral vectors cannot be generated at a high titer, it is not possible to get a large number of vector particles to the desired cell type in vivo. The viral particles would bind to many cells they encounter and therefore, would be diluted out before reaching their target.
The envelope protein has two functions: Binding to its Two broad approaches to providing target cell specificity have been followed. First, the natural receptor-binding domain of the SU protein has been replaced with a ligand or single-chain antibody that recognizes a specific cell surface receptor.
Although, several creative systems have been designed, the most successful approach at present appears to be insertion of a ligand that recognizes an extracellular matrix (ECM) component into a part of the SU protein that does not disturb the natural receptor-binding domain. This tethering concentrates the vector in the ECM in the vicinity of the target cells.
Receptor binding and core entry can then occur through the natural envelope-receptor mechanism. Two ligands that appear particularly useful for tethering are those specific for fibronectin for collagen. Fibronectin is present in normal ECM and exposed collagen is present in areas of damage, for example after wound injury as in the cardiovascular system after angioplasty. [2] [3] [4] 7, 8] Lentiviruses (e.g., human immunodeficiency virus type 1: HIV-1) are a special group of retroviruses with the ability to infect both proliferating and quiescent cells.
To expand the spectrum of target cells, it is possible to replace the genes for surface glycoproteins by genes from another viral genome in the packaging cell lines packaging cell lines (PCL) of the vector.
Lentiviral transfer systems ensure long-term expression
and efficient transfer without inflammatory responses. [4] [5] [6] 9] The adenovirus does not integrate its genome into the A replication-conditional mutant of HSV has been shown to elicit anti-tumor responses in pre-clinical models of glioma and metastatic colon cancer. [11] [12] [13] 
Poxviruses
The large potential size (25 kb) of the gene insert, the Because of their extensive host-cell toxicity and broad host range, alpha viruses are suitable for cancer gene therapy of various tumors. Many clinical trials have showed that intratumoral injection of recombinant alpha viruses induced apoptosis of tumor cells. The great potential of alpha viruses is also given by their immunogenicity and ability to induce cytotoxic T-cell responses. They are suitable for vaccine production and immunization against infectious agents, but also tumors. [2, 4, 7, 10, 14] 
Non-Viral Vectors
Non-viral vectors include naked-DNA and liposomes.
They are based on plasmid, which is a closed, circular DNA strand. Therapeutic genes can be inserted directly into the plasmid, and then this recombinant plasmid can be introduced into cells in a variety of ways. Delivery of wild-type (weight) p53 to a radiation-resistant squamous cell carcinoma cell line via this ligand targeted liposome complex was also able to modulate the radiation-resistant phenotype of these cells in vitro. These results indicate that this tumor-specific, ligand-liposome delivery system for p53 gene therapy, when used in concert with conventional radiotherapy, may provide a new and more effective means of cancer treatment. [1, 2, [4] [5] [6] [7] [8] [10] [11] [12] 
Bacteria as Vectors for Blocking Angiogenesis Gene Therapy

Bactofection
The use of bacteria as a vector for the delivery of therapeutic genes to target cells is known as bactofection,
and several studies have used this approach to deliver genes encoding anti-angiogenic molecules to tumor cells in vivo. However, if the product of the transgene is secreted outside the target cell, it may still have a therapeutic effect on non-infected tumor cells.
DNA vaccination
It is known that bactofection of plasmids encoding a tumor-expressed antigens can lead to induction of humoral and cellular immune response in the host thereby providing protective defense against tumors (R . Xiang et al., 2000) .
This approach, termed DNA vaccination, has been successfully implemented for anti-angiogenic therapy.
Alternative gene therapy
Another means of using bacteria for gene therapy is the so-called Alternative gene therapy (AGT) approach, which is also known as bacterial protein delivery. It is based on the transfer of bacterially expressed therapeutic proteins to the host organism using genetically modified (transformed) bacteria. As with bactofection, AGT is mostly used for treatment of tumors and employs primarily oncolytic and tumor-colonizing bacterial strains of Clostridia, Bifidobacteriaor Salmonellae.
Bactoference-bacteria-mediated RNA interference
Bacteria that have engineered to produce and deliver short interfering RNA represent a novel tool for the efficient induction of RNA interference in host cells.
Currently known and tested bacterial vectors can be divided into two groups. Strictly anaerobic bacteria (the species Clostridium and Bifidobacterium) are used in in vivo experiments. Clostridium is the most important bacterial species for use as a vector.
The second group consists of attenuated auxotrophic strains of Salmonella typhimurium that require the presence of tumor specific nutrition factors for selective replication. They use these factors for their own metabolism, thus, prohibiting the tumor cells from utilizing them and growing. [4, 12] 
Conclusion
Gene therapy is good for single gene defect but more research should be carried out for multiple gene defects. Viruses form good carrier of genes however, they also have their limitations. New and effective gene carriers need to be developed by further research to increase target specificity and decrease harm to adjacent healthy tissues. Gene therapy is very good method of treatment of genetic disorders and cancers.
